How Foundayo Works: Dosing Schedule, Side Effects, After-65 Evidence and How It Compares (2026)

Foundayo (orforglipron) is Lilly’s FDA-approved daily oral GLP-1 for weight management. The medicine starts at $149 for a 30-day self-pay fill, but the price rises with dose and can depend on refill timing. Lilly’s current terms, checked September 20, 2026, list $149 at 0.8 mg or promotional 2.5 mg, $199 at promotional 5.5 mg, and $299 at 9 mg. The 2.5 and 5.5 mg reductions run through December 31, 2026; their regular prices are $199 and $299. At 14.5 or 17.2 mg, $299 requires a qualifying refill within 45 days, otherwise the price is $349. Taxes or other fees may apply. A prescription is required. In the separate ATTAIN-1 trial, participants taking Foundayo lost 12.4% of body weight on average over 72 weeks. That result is not a personal forecast.

Quick answer: should you choose Foundayo?

• •YES, if you're needle-phobic or travel frequently: No injections, no fasting, no fridge required
• •YES, if you want the newest GLP-1: FDA-approved April 1, 2026, youngest approval on the market
• •COMPARE THE FULL PRICE, if cost matters: Foundayo starts at $149/mo but rises by dose and refill timing; NovoCare Wegovy pill also starts at $149/mo, while the pen is $199/mo for the first two low-dose fills before rising to $349/mo at standard strengths ($399 HD). Compare the prescribed strength and checkout total, not Foundayo's $649 list price against another drug's cash-pay offer
• •NO, if max weight loss is the goal: Tirzepatide (Zepbound) produces 20.9% vs Foundayo's 12.4%, see Wegovy vs Zepbound. For injectable semaglutide results month by month: semaglutide before and after timeline (14.9-20.7% depending on dose)
• •MAYBE, if you're choosing between pills: Oral Wegovy produced 16.6% in OASIS vs Foundayo's 12.4% in ATTAIN-1, separate trials rather than a head-to-head study. Both cash-pay floors start at $149/mo, while dosing and refill conditions differ. Compare: Foundayo vs Wegovy Pill · All oral GLP-1 pill options compared

This guide covers orforglipron's non-peptide mechanism (why it survives stomach acid without SNAC), the ATTAIN-1 and ACHIEVE-1 trial data, exact side effect percentages, the full dosing schedule, pricing across channels, and how it compares to Wegovy and Zepbound. Compare Foundayo against all options in our provider rankings or use the cost calculator.

What Is Foundayo and How Is It Different?

Foundayo's active ingredient, orforglipron, is a non-peptide small molecule GLP-1 receptor agonist. Every other GLP-1 on the market, Wegovy, Ozempic, Zepbound, Mounjaro, Rybelsus, is based on modified peptides (synthetic versions of natural hormones). This matters for a practical reason:

Peptides get destroyed in the stomach. That's why most GLP-1s are injections, and why oral semaglutide (Wegovy pill, Rybelsus) requires a special absorption enhancer called SNAC, which forces you to take it on an empty stomach with no more than 4 oz of plain water, then wait 30 minutes before eating or drinking anything else.

Orforglipron is not a peptide, so it survives the stomach on its own. No absorption enhancer needed. No food restrictions. No water restrictions. Take it any time of day, with or without meals. This is Foundayo's single biggest practical advantage over every other GLP-1 option.

Clinical Trial Results: How Much Weight Does Foundayo Help You Lose?

Foundayo was studied in the ATTAIN clinical trial program. The pivotal trial for obesity was ATTAIN-1, published in the New England Journal of Medicine.

ATTAIN-1 results (3,127 adults with obesity, 72 weeks):

For context, the STEP 1 trial showed injectable semaglutide (Wegovy 2.4mg) produced 14.9% weight loss at 68 weeks, and SURMOUNT-1 showed tirzepatide (Zepbound 15mg) produced 22.5% at 72 weeks. Foundayo's 11-12% falls below both, but it is a pill with zero dosing restrictions, which is a meaningful tradeoff for many patients.

ATTAIN-2 studied Foundayo in patients with obesity AND type 2 diabetes: 10.5% mean weight loss (22.9 lbs) plus a 1.8% reduction in HbA1c at the highest dose.

ATTAIN-MAINTAIN (the first study of its kind) showed that patients who switched from injectable semaglutide or tirzepatide to oral Foundayo maintained most of their weight loss, with modest regain of approximately 5 kg compared to 9 kg on placebo. This positions Foundayo as a viable oral maintenance option after initial injectable treatment.

What Are Foundayo's Side Effects?

Like all GLP-1 medications, Foundayo's most common side effects are gastrointestinal. The rates below are from the official FDA prescribing information:

Discontinuation rates due to side effects: 10% at the 17.2 mg dose vs 3.2% on placebo. Most GI side effects were mild to moderate, occurred during dose escalation, and decreased over time.

Boxed warning: Like all GLP-1 medications, Foundayo carries a boxed warning about thyroid C-cell tumors observed in rodent studies with other GLP-1 agonists. Notably, orforglipron itself did not produce tumors in rodents (it is not pharmacologically active in rodent GLP-1 receptors), but the class warning is required. Foundayo is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Five mild cases of pancreatitis were confirmed across the ATTAIN-1 trial. Patients should report severe, persistent abdominal pain to their healthcare provider immediately.

Foundayo Dosing Schedule

Foundayo uses a gradual titration schedule with six dose levels. Each step lasts at least 30 days to minimize GI side effects:

Total time to reach maximum dose: approximately 5 months. Your provider may adjust the pace based on your tolerability and response. Some patients achieve meaningful weight loss at the 9 mg or 14.5 mg dose and don't need to escalate to 17.2 mg.

How Much Does Foundayo Cost per Month?

Foundayo self-pay runs $149 to $349 a month depending on dose and refill timing. Eligible commercially insured patients may pay as little as $25 under the Lilly savings-card terms, and eligible Medicare Part D patients pay a $50 Bridge copay.

Foundayo pricing is structured by dose level, with self-pay prices available through LillyDirect:

Lilly savings card: Covers up to $100/month for a 1-month fill, $200 for 2-month, $300 for 3-month. Annual cap of $1,000. Expires December 31, 2026. Available to commercially insured patients. Check eligibility at foundayo.lilly.com.

For comparison, NovoCare lists oral Wegovy from $149/month and the pen at $199/month for the first two low-dose fills, then $349/month at standard strengths ($399 HD). Foundayo's higher strengths cost $299 only when the 45-day refill condition is met at 14.5 or 17.2 mg; otherwise they cost $349. See our full cost comparison across 37 providers for provider program fees and other options.

How Does Foundayo Compare to Other GLP-1 Medications?

Choose Foundayo if: Dosing convenience is your top priority. You want a pill you can take any time without food/water restrictions. You're switching from an injectable and want an oral maintenance option (ATTAIN-MAINTAIN trial supports this). You prefer a Lilly product and want to stay in their ecosystem (Zepbound → Foundayo step-down).

Choose Wegovy (oral or injection) if: Maximum weight loss matters most to you. You want fewer GI side effects with the pill form. Note: Both semaglutide (SELECT trial, obesity with established CVD) and orforglipron (ACHIEVE-4 trial, T2D) have demonstrated cardiovascular outcome benefits, SELECT specifically studied high-CV-risk weight loss patients while ACHIEVE-4 studied T2D. Discuss your cardiovascular history with your provider when choosing between the two.

Choose Zepbound if: You want the highest weight loss possible (20%+) and don't mind a weekly injection. The dual GIP + GLP-1 mechanism produces meaningfully more weight loss than any single-agonist option.

For a deeper comparison of the two oral options, see our Foundayo vs Wegovy Pill analysis. For dose-by-dose Wegovy medicine prices and separate program fees, use the Wegovy pill cost guide. For a broader drug comparison, read Semaglutide vs Tirzepatide.

Where to Get Foundayo Online

As of April 2026, Foundayo is broadly available across LillyDirect, telehealth platforms, and retail pharmacies:

LillyDirect Self Pay: Eli Lilly's direct-to-patient platform has accepted Foundayo prescriptions since April 6, 2026. Pricing is $149/month at 0.8 mg, $149 at 2.5 mg (promotion through December 31, 2026; regular $199), $199 at 5.5 mg (promotion through December 31, 2026; regular $299) or $299 at 9 mg, and $299 at 14.5 mg or 17.2 mg only when refilled within 45 days, otherwise $349. Visit LillyDirect.

Telehealth platforms listed Foundayo in April 2026: Ro, Sesame Care, Shed, and Found. Their program starting prices can include membership or consultation services and should not be read as the Foundayo medication price for every dose. Confirm the medication strength, provider fee, refill condition, and all-in checkout total. For the ordering flow, see our Foundayo walkthrough.

Retail pharmacies: Amazon Pharmacy (same-day delivery, LillyDirect-integrated), GoodRx, CVS, Walgreens, and most major independent pharmacies carry Foundayo as of April 2026.

Foundayo Eligibility: Who Qualifies?

Foundayo is FDA-approved for adults who meet the same criteria as other weight loss GLP-1 medications:

• •BMI of 30 or higher (obesity), OR
• •BMI of 27 or higher with at least one weight-related condition: type 2 diabetes, high blood pressure, high cholesterol, cardiovascular disease, obstructive sleep apnea, NAFLD/NASH, or PCOS
• •Must be 18 or older (not yet approved for adolescents, unlike Wegovy)
• •Use in combination with a reduced-calorie diet and increased physical activity

Not sure if you qualify? Use our GLP-1 eligibility checker for a quick preliminary assessment. A healthcare provider will make the final determination based on your complete medical history.

What does the evidence show about taking Foundayo after 65?

The 65 and over data exists, and the number that should move a decision is not the weight loss figure. A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 phase 3 trials examined 616 randomized adults aged 65 and older, 613 of whom were treated, and at Week 72 every Foundayo dose produced greater percent body weight loss than placebo in both trials, all at p<0.001 (Obesity Pillars post hoc analysis, full text, 2026). The same analysis reports that discontinuation due to adverse events ran at 9.1% in the 65 and over group against 6.0% in participants under 65, and inside the older group it reached 14.7% on 9mg and 13.6% on 17.2mg against 4.7% on placebo. Efficacy in older adults tracked efficacy in younger adults. The rate at which people stopped because of side effects did not.

Two caveats belong beside those percentages rather than underneath them. First, this is a post hoc subgroup of trials designed and powered to answer a different question, so it can describe what happened in older participants but cannot establish it the way a prespecified, powered comparison would. Second, the reported figures come from the efficacy estimand, which models the result as if all randomized participants had adhered to treatment as intended. Real world adherence is lower than that, so these numbers run higher than what a typical patient should expect from the same prescription. Both trials are registered with percent change from baseline in body weight at Week 72 as the primary endpoint (ATTAIN-1 registration, ATTAIN-2 registration).

Here is the Week 72 result by trial and by arm, with the number of participants aged 65 and older in each individual arm, because that is the number each percentage actually came from.

Two things about that table. The placebo confidence interval in ATTAIN-1 runs from -3.2 to 0.1, so its upper bound crosses zero, which means the weight change in older ATTAIN-1 placebo participants was not statistically distinguishable from no change at all. And if you see the figures 118, 135, 146 and 214 printed next to a single trial's percentage anywhere else, those are the treated arms pooled across both trials, not the arm sizes of either one. The three pooled Foundayo arms add to 399, which is exactly the count of Foundayo treated patients aged 65 and older reported in section 8.5 of the current prescribing information (Foundayo prescribing information, 2026).

The label and the paper both reach for the same reassuring word, and the numbers underneath it are worth reading yourself. Section 8.5 states there were "No overall differences in safety or effectiveness ... between patients 65 years of age or older and younger adult patients" (prescribing information, 2026), and the analysis concludes that the adverse event profile in older adults was generally consistent with the overall trial population. That same analysis reports discontinuation due to adverse events at 9.1% versus 6.0% for younger participants, and within the 65 and over group at 5.1% on 5.5mg, 14.7% on 9mg and 13.6% on 17.2mg against 4.7% on placebo (Obesity Pillars, 2026). At the two higher doses that is roughly triple the placebo discontinuation rate in older adults. Its own key takeaways also record that serious adverse events, major adverse cardiovascular events and renal events occurred at a higher rate in participants 65 and older, in the placebo arms as well as the Foundayo arms, which the authors attribute to higher baseline risk in an older population. Consistent is a fair description of the shape. It is not a reason to skip the tolerability conversation.

Where those two doses sit is the part worth acting on. The approved titration schedule starts at 0.8mg and steps through 2.5mg and 5.5mg before reaching a maintenance dose of 9mg, 14.5mg or 17.2mg (FDA, April 1, 2026). The two doses where discontinuation spiked in older participants, 9mg and 17.2mg, are maintenance doses rather than starting doses. In our reading, the older adult question is less about whether to start Foundayo and more about how far up the ladder to climb, which is a conversation to have with a prescriber before the first refill rather than after the third.

The prescribing information also carries warnings and precautions for the following (Foundayo prescribing information, 2026):

• •Acute pancreatitis.
• •Severe gastrointestinal reactions.
• •Acute kidney injury due to volume depletion.
• •Hypoglycemia.
• •Hypersensitivity reactions.
• •Diabetic retinopathy complications in patients with type 2 diabetes.
• •Acute gallbladder disease.
• •Pulmonary aspiration during general anesthesia or deep sedation.
• •Our Foundayo side effects page tracks the full labeled list as the label is updated.

One scope detail trips people up because of what the trials contained. Foundayo is approved for weight reduction and long term weight maintenance in adults with obesity, or overweight plus at least one weight related comorbid condition, alongside a reduced calorie diet and increased physical activity (FDA approval letter, NDA 220934, 2026). ATTAIN-2 enrolled participants with type 2 diabetes and the subgroup analysis reports HbA1c results, but that does not make Foundayo an approved diabetes medication. It is not approved for glycemic control in type 2 diabetes. The label also states that concomitant use with another GLP-1 receptor agonist is not recommended, which matters for anyone already on a weekly injection who is thinking about adding rather than switching. For how each oral option is licensed, see our oral GLP-1 comparison.

On muscle, the trials give a partial answer rather than none. The registered primary endpoint for both ATTAIN-1 and ATTAIN-2 is percent change from baseline in body weight, which measures the scale rather than body composition (ATTAIN-1, ATTAIN-2). Inside that limit the analysis reports two relevant things. There was no significant difference in percent change in muscle mass between the age groups in ATTAIN-1, which the authors read as an improved ratio of fat to lean mass. And adverse events possibly related to loss of lean muscle mass occurred at a higher rate in participants 65 and older, in the placebo arms as well as the Foundayo arms (Obesity Pillars, 2026). Both are age group comparisons rather than a powered body composition endpoint, and the authors list bone density and nutritional deficits among the outcomes these trials did not measure at all. Ask a prescriber how they intend to monitor it.

There is a harder limit for the oldest readers. The same label section reports that only 33 Foundayo treated patients, 1% of the treated population, were 75 or older, against 399 who were 65 or older (prescribing information, section 8.5, 2026). Essentially the whole older adult evidence base sits in the 65 to 74 band. Past 75, this is thin ground, and the decision rests on individual clinical judgment rather than on trial evidence.

Cost splits into two different questions after 65, and they have different answers. If you have Medicare, the retail price is often not the relevant number at all, because which coverage route applies to you changes what you actually pay by a wide margin. We keep live figures on the pages where they can be corrected rather than in article prose where they go stale, so start with the route that matches your situation:

• •Medicare route: the Medicare GLP-1 bridge enrollment guide carries the current copay and the enrollment steps.
• •Self pay route: the Foundayo hub lists every provider we track that carries it, with current pricing per provider.
• •Provider detail: Ro is one of those providers, and it is an affiliate partner. We earn a commission if a reader signs up through our link. That relationship does not change its editorial score or its position in any ranking on this site.
• •Whole cost modeling: the GLP-1 cost calculator puts medication, membership and coverage variables in one place.

Who funded the analysis is part of reading it. Eli Lilly, which makes Foundayo, funded the study. Four of the six authors are employees and shareholders of Eli Lilly and Company, and both remaining academic authors disclose Lilly money as well: consulting fees, honoraria and institutional research support in one case, institutional research funding and a consultant role in the other. All six authors therefore have a financial relationship with the sponsor. Lilly was involved in the study design and conduct, in the collection, management, analysis and interpretation of the data, and in the preparation, review and approval of the manuscript. The data analysis was performed by a Lilly employee, and medical writing support was funded by Lilly. To its credit, the paper states that the sponsor did not have the right to veto publication or to control which journal received the manuscript (Obesity Pillars, 2026). None of that makes the numbers wrong. It does mean the framing choices, including which outcomes get called comparable, were made inside the company that sells the drug.

This section was written by Iacob Pastina, Independent Researcher and Publisher, drafted with AI assistance and checked line by line against the primary sources listed at the end on August 26, 2026. Full citation for the subgroup analysis: Obes Pillars. 2026 Jul 14;19:100301. doi:10.1016/j.obpill.2026.100301 (full text, DOI).

Frequently Asked Questions About Foundayo

Is Foundayo the same as Zepbound?

No. Both are made by Eli Lilly, but they are different drugs. Zepbound contains tirzepatide (a dual GIP + GLP-1 agonist given as a weekly injection). Foundayo contains orforglipron (a GLP-1-only agonist taken as a daily pill). Zepbound produces greater weight loss (20%+ vs 11-12%), but Foundayo offers the convenience of an oral pill with no food restrictions.

Can I switch from Zepbound or Wegovy to Foundayo?

Yes. The ATTAIN-MAINTAIN trial specifically studied patients switching from injectable semaglutide or tirzepatide to Foundayo. Patients maintained most of their weight loss, with modest regain of about 5 kg over 52 weeks (vs 9 kg regain on placebo). Discuss the transition plan with your prescribing provider.

Does insurance cover Foundayo?

Commercial coverage must be checked with the exact plan, and Lilly's commercial savings card has separate eligibility terms. Since July 1, 2026, Foundayo has been included in the separate Medicare GLP-1 Bridge at $50 per approved monthly supply for eligible patients. It is not automatic Part D coverage. Medicare lists the program rules; our insurance checklist helps you ask the right questions, not confirm an individual policy.

Why are Foundayo's side effects higher than Wegovy pill?

Orforglipron is a partial agonist with a different signaling profile than semaglutide at the GLP-1 receptor. It favors cAMP signaling over beta-arrestin recruitment, which may partly explain the higher GI rates. That said, most side effects are mild to moderate, occur during dose escalation, and decrease over time. The 10% discontinuation rate at the highest dose is in line with other GLP-1 medications.

How long until I see results on Foundayo?

Based on clinical trial data, meaningful weight loss begins during the dose escalation phase (months 2-3) and continues to increase through month 6-8. The full titration to the maximum 17.2 mg dose takes approximately 5 months. Most patients in ATTAIN-1 who completed the full 72-week treatment period achieved 10%+ body weight loss.

Should a 70 year old take Foundayo?

That is a prescriber decision, and the evidence supporting it is real but limited. In a post hoc subgroup of 613 treated adults aged 65 and older, every Foundayo dose produced greater Week 72 weight loss than placebo in both ATTAIN-1 and ATTAIN-2, all at p<0.001, while discontinuation due to adverse events ran at 9.1% against 6.0% in participants under 65 (Obesity Pillars, 2026). Someone at 70 sits inside the 65 to 74 band where nearly all of that evidence lives, so it applies to them better than to any older group. The first thing to rule out is a personal or family history of medullary thyroid carcinoma or MEN 2, both of which are contraindications under the boxed warning (prescribing information, 2026).

Is there Foundayo data for people over 75?

Barely. The prescribing information reports that 33 Foundayo treated patients, 1% of the treated population, were 75 or older, against 399 who were 65 or older (prescribing information, section 8.5, 2026). The label states there were no overall differences in safety or effectiveness between patients 65 years of age or older and younger adult patients, but a 33 patient slice cannot carry that conclusion on its own for the oldest band. Past 75, treat this as a decision made on individual clinical judgment rather than on trial evidence.

The Bottom Line on Foundayo

Foundayo fills a real gap in what is available: it's the only weight loss pill you can take without thinking about food timing, water restrictions, or injection anxiety. The tradeoff is lower weight loss (~12%) compared to injectable options (~15-23%) and slightly more GI side effects than oral semaglutide.

For patients who have been on the fence about starting a GLP-1 because they don't want injections or can't deal with oral semaglutide's rigid dosing rules, Foundayo removes those barriers. For patients already on injectables who want to transition to a pill for long-term maintenance, the ATTAIN-MAINTAIN data supports that path.

At $299/month self-pay for maintenance doses (or as low as $25/month with commercial insurance + savings card), pricing is competitive with other brand-name options. The real question is whether your insurance will cover it yet, and that's a moving target as formularies update through mid-2026.

Not sure which GLP-1 is right for you? Our provider match quiz can pair you with the right program in under 2 minutes, or check the full provider rankings to compare all 37 telehealth options side-by-side.

Sources